This content is machine translated Practice Check Ozanimod in clinical routine Following approval of the new active ingredient in Switzerland, its use in practice is now being investigated. An important practical aspect of the drug is the oral route of administration.…
View Post 4 min This content is machine translated Tolerability Check On the downside: throat and liver In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in…
View Post 5 min This content is machine translated Safety Check Selectivity as a distinguishing feature Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment…
View Post 4 min This content is machine translated Efficacy Check Multiple levels of effectiveness The two completed phase III studies SUNBEAM [1] and RADIANCE [2] were able to demonstrate the efficacy of the new active substance in the area of other – radiological and…
View Post 5 min This content is machine translated Ozanimod A new player in MS therapy With the recently approved ozanimod, another potent compound for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated…
View Post 1 min This content is machine translated MS therapy today A new player in MS therapy With the recently approved ozanimod, another highly potent agent for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator…
